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Summary 
During  the  inflammatory  response,  the  adhesion  molecule  PECAM  plays  a  crucial  role  in 
transendothehal  migration,  the  passage  of leukocytes across endothelium.  We report here  an 
additional  role for PECAM in the subsequent migration of monocytes through the subendo- 
thelial extraceHular matrix. PECAM has six immunoglobulin (Ig) superfamily domains. Mono- 
clonal antibodies whose epitopes map to domains  1 and/or 2  selectively block monocyte mi- 
gration through the endothelial junction, whereas those that map to domain 6 block only the 
migration through the  extracellular matrix,  trapping the monocyte between the  endothelium 
and its basal lamina. Therefore, transendothelial migration (diapedesis) and passage through ex- 
tracellnlar matrix  (interstitial  migration)  are distinct and separable phases of monocyte emigra- 
tion. Furthermore, distinct and separate Ig domains of PECAM are involved in mediating these 
two steps. 
D 
uring  the  final  stages  of emigration  from the  blood- 
stream into a site of inflammation,  white blood cells, 
or leukocytes, squeeze between tightly apposed endothelial 
cells  (EC) 1 of the vascular wall without disrupting vascular 
permeability. This transendothehal migration (TEM) involves 
platelet/endothelial  cell  adhesion  molecule-1  (PECAM, 
CD31),  which  is  expressed  on  the  surfaces  of leukocytes 
and  concentrated  along  the  borders  between  ECs  (1,  2). 
PECAM is composed of six extracellular immunoglobulin 
domains  (2).  A  homophilic interaction  (i.e.,  an interaction 
between neutrophil or monocyte PECAM and endothelial 
PECAM)  is  required  for  TEM.  When  antibody  to 
PECAM is applied to either the leukocyte or endothelium, 
TEM  is  blocked  both  in vitro  and  in vivo  (3-6).  Less  is 
known  about  the  subsequent  migration  of  leukocytes 
through the endothelial basal lamina and the interstitial ma- 
trix.  Using quantitative  in vitro assays that dissect different 
steps  in  leukocyte  transit,  we  now  demonstrate  an  addi- 
tional role for PECAM just after the leukocyte has crossed 
the endothelial junction. This role is mediated by a domain 
of PECAM distinct from those involved in transendothelial 
migration  and  appears  to involve heterophilic  interactions 
1Abbreviations used in this paper: EC, endothelial cells; HUVEC, human 
umbilical vein endothelial cells; Mo, monocytes; N-CAM,  neural cell 
adhesion molecule;  Ng-CAM,  neuron-glial  cell adhesion molecule; 
PECAM, platelet/endothelial cell adhesion molecule-I; TEM, transen- 
dothelial migration. 
of leukocyte PECAM with components of the extracellular 
matrix. 
Materials and Methods 
Construction of Truncated PECAM-IgG Chimeric Proteins.  A  full- 
length  PECAM-IgG  cDNA  was  constructed  by  interrupting 
PECAM cDNA at the putative membrane insertion site with a 
NotI site and ligating with a cDNA encoding the hinge and CH2 
and CH3 regions  of human IgG1  (generously provided by Drs. 
Mickey Hu and Mark Zukowski of  Amgen, Inc. Thousand Oaks, 
CA), and subsequently  subcloned into the expression vector pcD- 
NAI/Neo  (Invitrogen,  San  Diego,  CA).  PC1K technology was 
used  to produce a series of PECAM constructs  differing  by the 
addition of a complete 3' domain. A common 5' primer and a se- 
ries of 3' primers engineered with HindlII and NotI sites, respec- 
tively, were used to amplify DNA encoding only the desired seg- 
ments of PECAM (2, 7). These were then ligated into pcDNAI/ 
Neo and rejoined with hlgG in a separate step. The sequence of 
the  5'  primer  was  5'-TCAG  TAGACCACCATG- 
CAG-3'. The shaded area represents  the HindlII site. The initia- 
tor ATG codon is underlined.  The sequences  of the 3' primers 
were; 
1.  5'-TAGAATATC  TTGTATGGCCTCTTT-3' 
2.  5'-TAGAATATC  TTCCATGATCATTCC-3' 
3.  5'-TAGAATATC  TTGGTCCAGATGTGT-3' 
4.  5'-TAGAATATC  TTCGATGGTCTGTCC-3' 
5.  5'-TAGAATATC  AGACTCCACCACCTT-3' 
The shaded areas mark the NotI restriction  site. 
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cells were  transiently transfected with each of the PECAM-IgG 
constructs of the 3' deletion series as well as full-length PECAM- 
IgG.  20  p,g of plasmid was  added  to  107  Cos  cells in  0.5  ml of 
DME  medium in a  4  mm cuvette and subjected to  electropora- 
tion at 960 p~F, 250 mV in a gene pulser (Bio-Rad,  Richmond, 
CA)  (3).  Transfected cell culture  supernates  were  collected  and 
subjected  to  SDS-PAGE  under  nonreducing  conditions.  The 
4-11%  gradient  gel  was  electroblotted  onto  Immobilon  mem- 
brane (Millipore Corp.,  Bedford, MA)  and probed with an alka- 
line phosphatase-labeled goat anti-human Fc antibody and devel- 
oped with NBT/BCIP as the substrate (2). 
Monoclonal Antibody  Binding ELISA,  An ELISA assay was de- 
veloped to map the epitopes recognized by a panel ofanti-PECAM 
mAb. Rabbit anti-mouse IgG was adsorbed to ELISA plates fol- 
lowed by blocking in phosphate buffered saline +  0.1% ovalbu- 
min.  100 Ixl of monoclonal antibody supernate or 1 Ixg of puri- 
fied  IgG  were  added  to  each  well  in  a  column  and allowed  to 
bind for 1 h at room temperature. After washing, 100 t*1 of culture 
medium from Cos cells transfected with each truncated PECAM- 
IgG construct were added to the plates for 1 h  at room tempera- 
ture.  After extensive washing, binding of the PECAM  chimeras 
was detected using Alkaline phosphatase-labeled goat anti-human 
Fc in the Attophos assay,  as described (8, 9). MAb P1.1, P1.2, and 
P1.3 were provided by Dr.  Peter Newman  (Blood Center of SE 
Wisconsin);  mAb  4G6  by  Dr.  Steven  Albelda  (University  of 
Pennsylvania,  Philadelphia,  PA);  mAb  L133.1  was  purchased 
from Becton-Dickinson (San Jose, CA). 
Human  Umbilical Vein Endothelial Cell  Culture, Leukocyte Isola- 
tion,  and  Transendothelial Migration Assays.  These  were  all  per- 
formed as  described in detail in references  l,  10,  and 3,  respec- 
tively. Briefly, human umbilical vein endothelial cells (HUVEC) 
were  grown  to  confluence on hydrated Type  I  collagen gels  in 
the  presence  of 20%  normal  human  serum  without  additional 
growth  factors.  Peripheral blood mononuclear cells were  added 
to  the medium above these monolayers  and monocyte-selective 
transendothelial migration (10) was allowed to proceed for 1 or 2 
hours in the presence of anti-PECAM reagents or controls.  The 
monolayers  were  then  treated  as  described  (3).  Monocytes  ar- 
rested on the apical surface were identified by their ability to bind 
hl0d;  ~H~  1  -  -  +  - 
hlgGu  (~.~..~H2  2  +  -  -P  -  + 
hlgGH  ~~.~H2  3  "1"  -  "t"  "4" 
hlgG--'---~ ~H2 
hlgG'---'~ ~H2 
h  I  g  G-"~  ~H2 
Reactivity of Anti-PECAM mAb 
uct~  with  Truncated PECAM 
Constr  hec7  P1.1  P1.2  P1.3  4G6  L133.1 
0 
4  +  -  +  -  + 
5  +  +  +  + 
6  +  +  +  +  +  + 
Figure  1.  (a)  Schematic  diagram of the  strategy  for 
constructing truncated PECAM molecules.  A portion 
of the pcDNAl/Neo vector containing cDNA for the 
signal sequence (SS, shaded box) and the six extracellu- 
lar immunoglobulin domains of PECAM  fused  at an 
engineered NotI site to a sequence encoding the hinge, 
CH2, and C.3 domains of the human IgG heavy chain 
(hlgG) is shown.  (b) Western blot of series of sequen- 
tially truncated PECAM-IgG chimeras.  Lanes  1-5 in- 
dicate  the  position  of sequentially  longer  constructs 
made by primers 1-5 in part A. Lane 6 shows the full- 
length  PECAM-IgG.  Lane  0  shows  supernate  from 
mock transfected  Cos. Numbers on the left indicate the 
positions of molecular mass standards. Bands  I-6 run at 
the  expected positions  for dimers of N80,  110, 140, 
170, 200, and 230 kD,  respectively.  Note that essen- 
tially all of the detectable molecules  are running as in- 
tact  dimers.  (c)  Schematic  diagram  of PECAM-IgG 
constructs  1-6  and  the  reactivity  of  various  anti- 
PECAM mAb, as determined by ELISA assay. Lack of 
reactivm' above background is indicated by -, whereas all wells with a +  were generally  40-100￿  above background levels. Rabbit anti-mouse mAb 
adsorbed  to ELISA plates was used to bind the various  mAb placed in each well in the vertical  column. Cos supemates containing constructs 1-6 or 
mock transfected  Cos supernate (0) were placed in each row across. Binding of the PECAM chimeras was detected using Alkaline phosphatase-labeled 
goat anti-human Fc. 
1338  Separate Domains of PECAM Mediate Distinct Phases of Monocyte Emigration Figure 2.  Only mAb binding to PECAM domains 1 and/or 2 block TEM ofMo. PBMC were incubated with the indicated mAb at 20 I~g/ml, or he- 
parin or dextran sulfate (Sigma Chemical Co., St. Louis, MO) at 50 ~g/ml and added to HEC monolayers for 2 h at 37~  (concentrations previously 
found to block optimally [3, 14]). The monolayers were washed with EGTA to remove unbound and integrin-bound leukocytes. The percent of cells  re- 
maining associated  with the HEC that had transmigrated below the monolayer was quantitated as described (3). Approximately 100 cells were counted 
for each replicate monolayer. The bars represent the mean and standard error for six replicate monolayers. In cases  where two m.Ab were added, the con- 
centration of each was 20 ~g/ml. W6/32 is a mAb against Class I MHC antigen used as a negative control (3). PECAM-IgG is the full-length PECAM- 
IgG chimera containing domains 1-6. Two independent experiments are shown as a and b. 
IgG- or C3bi-coated sheep  erythrocytes. Transmigrated mono- 
cytes were  at  a  lower focal plane  and  did not  bind  opsonized 
erythrocytes (3). 
Interstitial Migration Assay.  To  quantitate  migration into  the 
gel, the fixed, Wright/Giemsa stained monolayers were examined 
by Nomarski optics at 400￿  The microscope was focused on the 
apical surface  of the monolayer. The fine focus was then moved 
slowly through  serial increments  of 5  Ixm and  the  number  of 
monocytes (Mo) within that level were scored. 
Electron Microscopy.  Electron  microscopy was  performed  by 
standard  techniques  essentially as  described  (1).  Monolayers of 
HUVEC on collagen were fixed in half-strength Karnovsky's fix- 
ative and postfixed with osmium tetroxide prior to embedding in 
Epon. Cross-sections of the monolayer were cut on a Reichert- 
Jung  ultramicrotome  and  viewed  on  an  electron  microscope 
(JEOL 100 CX-II, JEOL U.S.A. Inc., Peabody, MA). 
Results  and Discussion 
Anti-PECAM monoclonal antibody (mAb) hec7  blocks 
TEM  of Mo  and  neutrophils  (PMN)  in  a  quantitative  in 
vitro assay (3). The block is selective for TEM. There is no 
diminution of the ability of the leukocytes to adhere to the 
apical  surface  of the  ECs;  rather,  the  leukocytes  remain 
tightly  adherent  over  the  intercellular borders,  reversibly 
arrested in  their transendothelial passage  (3).  Not  all anti- 
PECAM  mAb block TEM;  functional studies in  conjunc- 
tion with mAb mapping were used to determine which ex- 
tracellular domains of PECAM are critical for TEM. 
The  extracellular portion  of PECAM  is organized into 
six Ig domains (2). A series of sequentially truncated PECAM- 
IgG chimeras were synthesized in order to map the epitopes 
of a panel of mAb (Fig.  1  a). The  truncated PECAM-IgG 
chimeras  ran  at  the  expected  molecular  mass  on  nonre- 
duced SDS-PAGE  (Fig.  1  b).  In an ELISA the mAb P1.3 
bound to all of the constructs containing domain 1, includ- 
ing the shortest containing only domain 1 (Fig. 1 c). Binding 
of hec7  and L133.1  required expression of both domains 1 
and  2.  PI.1  bound  only to  the  constructs  containing do- 
main  5,  whereas  the  mAbs P1.2  and  4G6  bound  only to 
full-length constructs  containing domain  6  (Fig.  1  c).  We 
will refer to  hec7  and L133.1  as domain  1  and/or 2  mAb 
and P1.2  and 4G6  as domain 6  mAb, although these con- 
structs alone  cannot  assign the  domain of the  epitope un- 
ambiguously. Nevertheless, our results are consistent with a 
recently published study in which a different technique was 
used to identify the epitopes of anti-PECAM mAb (11). 
All mAb used in these experiments bind to Mo equiva- 
lently. However, only the three mAb that bound to PECAM 
domain 1 and/or 2 blocked TEM in our in vitro assay (Fig. 
2).  In a  representative experiment hec7,  L133.1,  and Pl.3 
blocked  TEM  of Mo  by  73,  67,  and  70%,  respectively, 
whereas mAb P1.1,  P1.2,  and 4G6  had no  effect  (Fig. 2). 
Under the conditions used in these experiments, the mAb 
exerts  its  effect  by binding  to  monocyte  PECAM  rather 
than the endothelial PECAM  (3). 
Our assay employs direct visualization of the interacting 
cells to assess the final positions of Mo in relation to the en- 
dothelial monolayer.  Mo  treated with  anti-PECAM  mAb 
that  recognized domain  6  migrated across the  endothelial 
monolayer. Once under the monolayer, however, they re- 
mained close to  the  abluminal surface  of the  endothelium 
instead  of migrating  deep  into  the  collagen  gels,  as  Mo 
treated with control mAb. Fig. 3  quantitates the migration 
of Mo below the monolayer (interstitial migration). By two 
hours,  control  Mo  were  distributed  among  all  six  levels 
with  less  than  20%  remaining  in  the  uppermost  10  Ixm. 
MAb hec7, L133.1, and P1.3 blocked TEM; however, the 
fraction of Mo that did transmigrate moved into the gel as 
deeply  as  control  cells.  In  contrast,  80-90%  of the  Mo 
treated with anti-domain 6  mAbs P1.2 or 4G6 were still in 
the uppermost 10 Ixm, close to the basal surface of the ECs, 
after  2  h.  Similar results were  seen  when  the  incubation 
time was extended to 4 h  (not shown). 
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are  mediated  by  separate  domains  of the  PECAM  mole- 
cule.  Combining  mAb  P1.2  and hec7  did  not  change  the 
ability of hec7 to block TEM  (Fig.  2  b), nor did it alter the 
ability of P1.2  to block migration of Mo  into  the  collagen 
gel  (Fig.  3  b). The  domains required for TEM  and intersti- 
tial migration are spatially separated, since mAb P1.1,  which 
binds  domain  5,  had  no  effect  on  either function  (Figs.  2 
and 3). 
Figure 3.  PECAM-dependent mi- 
gration  into  the  collagen  gel  is 
blocked by mAb that bind to do- 
main 6 and by heparin. Far fewer 
Mo  migrated into  the  gel  in  the 
samples treated with hec7, P1.3, or 
L133.l  mAb,  but  those  that  did 
migrated  as  deep  as  control  Mo. 
Parts  A  and  B  correspond  to  the 
identical  experiments  in  Fig.  2. 
Note that level  1 begins immedi- 
ately below the basal surface of the 
endothelial cell; most Mo in level 
1 in the samples treated with P1.2, 
4G6,  or heparin were seen in the 
superficial  portion  of  that  level, 
immediately beneath the EC. Data 
using anti-domain 6 mAb or hep- 
arin are  shown in black bars; data 
using other reagents  are  shown in 
shaded bars. The data are expressed 
as the percentage of total cells be- 
low the HEC monolayer that were 
seen at each level.  The mean and 
standard  errors  for  six  replicate 
samples  are  given  for  part  b;  for 
part  a  the  mean  of six  replicate 
samples  is given,  the standard  er- 
rors  were all less than 10% of the 
mean  value.  >100  cells  were 
counted  for  each  of six  replicate 
monolayers  for each  sample,  thus, 
more  fields  were  counted  for 
hec7-,  P1.3-,  and  L133.1-treated 
samples. 
An experiment identical to that of Fig.  3  was performed, 
but  this  time  cultures  were  fixed  and  embedded  in Epon. 
Depth  of Mo  migration was  quantitated in  1-~,m  sections 
cut perpendicular to the endothelial monolayer,  and similar 
results were  obtained  (not  shown).  This material was  then 
examined by electron microscopy.  Many of the cells treated 
with  anti-domain  6  mAb  were  retained between  the basal 
surface  of the EC  and the basal lamina  (Fig.  4,  b and c).  In 
Figure 4.  Monoclonal antibodies against different  domains of PECAM block monocyte migration at two distinct steps. Mo were allowed  to interact 
with HEC monolayers for two hours in the presence ofanti-PECAM mAb hec7 (a), P1.2 (b), or 4G6 (c) all at 20 ~g/ml final concentration. Monolayers 
were then fixed and processed for electron microscopy,  a shows the typical profile of an adherent monocyte (Mo) blocked from transmigrating the endot- 
helial cell (EC) junction by mAb hec7, as had been previously  demonstrated (3). Small arrows mark the edges of the interendothelial cell border. Large 
arrows point to the amorphous fuzzy endothelial cell basal lamina (BL). Note monocyte filopodia probing the apical surface of the EC. b and c show the 
appearance  of typical monocytes still in contact with the undersurface  of the EC in the presence of anti-domain 6 mAb P1.2 and 4G6, respectively.  They 
have migrated through the interendothelial  junction (small arrows) and he between the basal surface of the EC and the endothelial basal lamina (BL, large 
arrows). Note filopodia probing through the BL into the underlying collagen gel, which extends well beyond the field of this photograph. CF (open arrow) 
shows a collagen fibril. Bar,  1 /,zm. 
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fying the putative domains responsible  for TEM and interstitial migration 
and bearing the epitopes recognized by the mAb described in the text. 
contrast,  mAb  hec7  blocked  TEM  at the  apical  surface  of 
the EC  (Fig. 4  a), as previously demonstrated  (3). 
As  previously  mentioned,  PECAM  on  a  leukocyte  can 
bind in a homophilic manner to PECAM on the EC (3), but 
PECAM-transfected L cells can also aggregate in a PECAM- 
dependent  heterophilic  manner  (12-15).  Heparan  sulfate 
proteoglycans  are  ligands  for  this  heterophilic  adhesion. 
However,  to  date  there  has  been  no  known  physiologic 
function  for  the  binding  of PECAM  to  proteoglycan.  It 
was  apparent  that  the  ability  of mAb  to  inhibit  interstitial 
migration  exactly paralleled  their  ability to inhibit  hetero- 
philic  aggregation  of PECAM-transfected  L  cells.  In those 
published  experiments,  P1.2  and  4G6  inhibited,  but  hec7, 
L133.1,  P1.1  and P1.3 were inactive  (15)  (and unpublished 
results).  Heparin  at  50  p~g/ml  (and  heparan  sulfate,  not 
shown),  which  blocked  heterophilic  aggregation  (14,  15) 
similarly  inhibited  migration  through  extracellular  matrix 
(Fig.  3).  This was a specific effect of heparin,  since dextran 
sulfate,  a  similarly charged polymer used  at the  same con- 
centration,  had no effect. Neither polymer had a significant 
effect on TEM  (Fig.  2).  The site(s)  on PECAM  that inter- 
act with  heparin  have  not  been  defined.  Conversely,  full- 
length  PECAM-IgG,  which would be expected to interact 
homophilically with PECAM on Mo blocked TEM  (Fig. 2 
a) but had no effect on interstitial migration  (Fig.  3 a). 
We conclude that while the homophilic interaction of the 
amino-terminal region of leukocyte PECAM with PECAM 
of the EC  is involved in transendothelial  migration  per se, 
heterophilic  interaction  of the membrane-proximal  region 
of leukocyte  PECAM  with  heparan  sulfate  proteoglycans 
(such as perlecan) in the endothelial basal lamina, and possi- 
bly  deeper  in  the  interstitial  tissues,  is  involved  in  the 
movement of transmigrated  leukocytes  through  the  extra- 
cellular matrix. A  schematic diagram of the PECAM mole- 
cule with its mAb epitopes and putative functional domains 
is shown in Fig. 5. Whether interaction with proteoglycans 
serves this function by promoting adhesion directly, via ac- 
tivating  leukocyte  integrins  (9,  16,  17),  or  by  stimulating 
monocyte secretion  of matrix-degrading  proteases is under 
investigation. 
Only  two  other  adhesion  molecules,  neuron-glial  cell 
adhesion  molecule  (Ng-CAM)  (18)  and  neural  cell  adhe- 
sion molecule  (N-CAM)  exhibit both homophilic and het- 
erophilic binding functions.  N-CAM  binds to itself via do- 
main 3  (19) and to heparin via domain 2  (20). The domains 
responsible for the adhesive interactions  of Ng-CAM  with 
itself  (18)  or  the  heterophilic  ligands  laminin  (21)  and 
chondroitin  sulfate  proteoglycans  (22,  23)  have  not  been 
identified.  The  leukocyte  integrin  VLA-4  (c~4131) has  been 
shown to bind heterophilically to two different ligands,  the 
endothelial  cell  adhesion  molecule  VCAM-1  and  the  ma- 
trix  molecule  fibronectin  via  two  separate  domains  (24). 
The  endothelial  adhesion  molecule  MAdCAM-1  supports 
rolling  interactions  with  lymphocyte  o~4~  7  (25)  as  well  as 
L-selectin  (26),  presumably via Ig-like and  mucin-like  do- 
mains, respectively. However,  the present report is the first 
description of a leukocyte-endothelial cell adhesion molecule 
that utilizes  distinct  domains  for two  different  mechanisms 
of interaction  (homophilic  and  heterophilic),  to  mediate 
two separate and sequential  functions,  transendothelial  mi- 
gration and migration through  extracellular matrix,  respec- 
tively. 
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1342  Separate Domains of PECAM Mediate Distinct Phases of Monocyte Emigration Note added in proof: In experiments performed recently, mAb NIH 31.4  (kindly supphed by Dr.  Stephen 
Shaw, NIH), whose epitope is in domain 2 of  PECAM-1 (11), blocked TEM, but to about half  the extent of  the 
other antibodies at similar concentrations. It had no efffect on interstitial migration. The peptide LKREKN 
(14) had no effect on either TEM or interstitial migration at concentrations up to 1 mg/ml (1.25 mM). 
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